Merck KGaA has formed a collaboration agreement with Iktos for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds.   “This agreement is another illustration of how we aim to enrich our discovery engine with strategic technology-focused collaborations,” said Belén Garijo, chief executive officer, healthcare, Merck KGaA. “Artificial intelligence is emergin...